Abstract
Methotrexate (MTX) and cyclosporine (CYC) may adversely interact with common medications in patients with psoriasis. Our purpose was to investigate the prevalence and outcomes of MTX/CYC polypharmacy. We evaluated rates of events that may be associated with drug-related toxicity, health care resource utilization and costs for patients with psoriasis in the Ingenix(R) Impact National Managed Care Database (1999-2007) who were exposed or not exposed to potential drug-drug interactions. Among 4,583 (57.6%) exposed and 3,372 (42.4%) nonexposed patients, nonsteroidal anti-inflammatory drugs and antibiotics were the most common drugs with potential interactions. The exposed patients had significantly greater risks of developing renal [adjusted odds ratio (OR): 2.58; p = 0.0145], gastrointestinal (OR: 1.36; p = 0.0197) and pulmonary events (OR: 1.20; p = 0.0470), and significantly greater health care resource utilization (e.g. OR for inpatient and emergency department visits: 1.47; p < 0.0001) and costs (adjusted incremental cost: USD 1,722; p < 0.0001). MTX/CYC polypharmacy is prevalent in patients with psoriasis and associated with significant risks.
Citations
Jul 20, 2012·International Journal of Clinical Pharmacy·Barbara O M ClausHugo Robays
Aug 22, 2013·Expert Reviews in Molecular Medicine·Andrew K BaldwinCay M Kielty
May 15, 2013·Health and Quality of Life Outcomes·Vibeke StrandKim A Papp
Feb 26, 2014·Drugs·Philip J Mease, April W Armstrong
Mar 22, 2013·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Karolina PazianaVincent Armenti
May 18, 2011·Journal of Medical Economics·Kent H SummersRobert Ohsfeldt
Dec 15, 2010·Current Medical Research and Opinion·Keith FreemanJacob Ryttov
Oct 16, 2015·Nanoscale·Youngmin SeoJonghoon Choi
Jul 4, 2012·Lancet·Kim PappRobert M Day
Sep 29, 2011·Pain Practice : the Official Journal of World Institute of Pain·Joseph V PergolizziKent H Summers
Jul 19, 2012·Arthritis and Rheumatism·Georg SchettKurt L de Vlam
Oct 4, 2012·Journal of the European Academy of Dermatology and Venereology : JEADV·K A PappP Rohane
Sep 3, 2010·Pain Practice : the Official Journal of World Institute of Pain·Joseph V PergolizziKent H Summers
May 29, 2012·The Journal of Dermatological Treatment·Atsuyuki IgarashiBrad Schenkel
Apr 14, 2015·Expert Opinion on Pharmacotherapy·Hunar AbdulrahimAlvin Wells
Sep 3, 2016·BMC Research Notes·Fantaye TekaTerefe Teshome
Sep 8, 2016·Journal of the European Academy of Dermatology and Venereology : JEADV·C E M GriffithsC Mamolo
Nov 8, 2011·Dermatology : International Journal for Clinical and Investigative Dermatology·Tatsuya NishiokaKozo Hashimoto
Sep 22, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·U MrowietzR B Warren
Apr 17, 2013·The Journal of Rheumatology·Vibeke StrandRandall M Stevens
Apr 26, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Richard N Herrier
Mar 30, 2019·Journal of Cellular Physiology·Ramyar AziziMehdi Yousefi
Aug 29, 2019·Expert Opinion on Pharmacotherapy·Hunar AbdulrahimAdewale O Adebajo
Aug 1, 2020·Journal of the European Academy of Dermatology and Venereology : JEADV·J L W LambertR Speeckaert
Aug 11, 2020·Drugs & Aging·Nico Shary, Robert E Kalb